Approval · Notice of Compliance 38264 · 2026
FLUMIST: Notice of Compliance 38264
Issued September 11, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38264
- Date
- September 11, 2026
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Annual update – strain changes
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FLUMIST | Not yet assigned | — |
Medicinal ingredients
- INFLUENZA VIRUS TYPE A (H1N1) 32,000,000 FFU per 0.2ML
- INFLUENZA VIRUS TYPE A (H3N2) 32,000,000 FFU per 0.2ML
- INFLUENZA VIRUS TYPE B (VICTORIA) 32,000,000 FFU per 0.2ML